Cytek Biosciences Inc Revenue Growth Rates (CTKB), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cytek Biosciences Inc   (NASDAQ: CTKB)
 

CTKB's Revenue Growth by Quarter and Year

Cytek Biosciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CTKB/growth
https://api.csimarket.com/api/v1/companies/CTKB/fundamentals
https://api.csimarket.com/api/v1/companies/CTKB/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
CTKB Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 53.23
2nd Quarter June 48.14
1st Quarter March 43.25
FY 144.62

CTKBs Annual Revenue
Cytek Biosciences Inc 's Revenue in the fiscal year 2025 $ 201.46 millions
Cytek Biosciences Inc 's Revenue in the fiscal year 2024 $ 200.11 millions
Cytek Biosciences Inc 's Revenue in the fiscal year 2023 $ 192.43 millions
Cytek Biosciences Inc 's Revenue in the fiscal year 2022 $ 164.04 millions
Cytek Biosciences Inc 's Revenue in the fiscal year 2021 $ 127.95 millions




CTKB Revenue third quarter 2026 Y/Y Growth Comment
Cytek Biosciences Inc reported Revenue growth of 3.26% year on year in the third quarter 2026, to $ 53.23 millions, this is lower than Cytek Biosciences Inc 's recent average Revenue increase of 16.11%.

Looking into third quarter 2026 results within Laboratory Analytical Instruments industry 8 other companies have achieved higher Revenue growth. While Cytek Biosciences Inc ' s Revenue increase of 3.26% ranks overall at the positon no. 2230 in the third quarter 2026.


CTKB Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 3.26 %
2nd Quarter June 5.57 %
1st Quarter March 5.08 %
FY   -

Financial Statements
Cytek Biosciences Inc 's third quarter 2026 Revenue $ 53.23 millions CTKB's Income Statement
Cytek Biosciences Inc 's third quarter 2025 Revenue $ 51.55 millions Quarterly CTKB's Income Statement


CTKB Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.57 %
2nd Quarter June 11.31 %
1st Quarter March -30.4 %
FY (Year on Year)   -


Back to CTKB Growth rate Comparisons >> Back to CTKB Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #9
Healthcare Sector #325
Overall #2230

Revenue Y/Y Growth Statistics
High Average Low
58.9 % 16.11 % -6.49 %
(Mar 31 2022)  
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #9
Healthcare Sector #325
Overall #2230
Revenue Y/Y Growth Statistics
High Average Low
58.9 % 16.11 % -6.49 %
(Mar 31 2022)  

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Cytek Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
32.56 % 5.81 % -30.39 %
(Jun 30 2023)  


CTKB's III. Quarter Q/Q Revenue Comment
Cytek Biosciences Inc achieved in the III. Quarter 2026 above company average sequential Revenue rise of 10.57%, to $ 53.23 millions, from $48.14 millions in the second quarter.

Within Laboratory Analytical Instruments industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Cytek Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 763.


Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #3
Healthcare Sector #123
Overall #763
Revenue Q/Q Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry #3
Healthcare Sector #123
Overall #763
Revenue Q/Q Growth Statistics
High Average Low
32.56 % 5.81 % -30.39 %
(Jun 30 2023)  


CTKB's III. Quarter Q/Q Revenue Comment
Cytek Biosciences Inc achieved in the III. Quarter 2026 above company average sequential Revenue rise of 10.57%, to $ 53.23 millions, from $48.14 millions in the second quarter.

Within Laboratory Analytical Instruments industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Cytek Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 763.


Cytek Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 205.09
Y / Y Revenue Growth (TTM) 4.41 %
Year on Year Revenue Growth Overall Ranking # 2647
Seqeuential Revenue Change (TTM) 1.25 %
Seq. Revenue Growth (TTM) Overall Ranking # 2671


Cumulative Revenue growth Comment
Although Cytek Biosciences Inc 's Annual Revenue growth year on year were below company's average 14.19% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 4.41% year on year, from 2.69% in Mar 31 2026.

In the Healthcare sector 378 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2555 to 2647.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 17
Healthcare Sector # 379
Overall # 2647

Revenue TTM Y/Y Growth Statistics
High Average Low
39.97 %
 14.19 %
-1.74 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 381
S&P 500 # 2671
Cumulative Revenue growth Comment
Although Cytek Biosciences Inc 's Annual Revenue growth year on year were below company's average 14.19% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 4.41% year on year, from 2.69% in Mar 31 2026.

In the Healthcare sector 378 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2555 to 2647.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 17
Healthcare Sector # 379
Overall # 2647

Revenue TTM Y/Y Growth Statistics
High Average Low
39.97 %
14.19 %
-1.74 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 381
S&P 500 # 2671




Other Revenue Growth
Laboratory Analytical Instruments Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CTKB's Revenue Growth Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Genedx Holdings Corp 5.64%$ 5.642 millions
Adma Biologics Inc 5.59%$ 5.595 millions
Innoviva Inc 5.55%$ 5.551 millions
Universal Health Services Inc 5.30%$ 5.297 millions
Acadia Healthcare Company Inc 5.14%$ 5.136 millions
Lumexa Imaging Holdings Inc 5.03%$ 5.032 millions
Bio techne Corp4.75%$ 4.753 millions
Merck and Co Inc 4.68%$ 4.683 millions
Davita Inc 4.62%$ 4.617 millions
Sotera Health Company4.61%$ 4.613 millions
Avantor Inc 4.59%$ 4.588 millions
Icu Medical Inc4.39%$ 4.388 millions
Illumina Inc 4.15%$ 4.151 millions
Agenus Inc4.14%$ 4.144 millions
United Therapeutics Corporation4.13%$ 4.128 millions
Option Care Health Inc 4.09%$ 4.086 millions
Henry Schein Inc 3.95%$ 3.953 millions
Grail Inc 3.71%$ 3.705 millions
Docgo Inc 3.70%$ 3.702 millions
Hca Healthcare Inc 3.59%$ 3.591 millions
Collegium Pharmaceutical Inc 3.43%$ 3.427 millions
Healthcare Services Group Inc 3.29%$ 3.288 millions
Cytek Biosciences Inc 3.26%$ 3.255 millions
Zimmer Biomet Holdings Inc 3.07%$ 3.073 millions
Ardent Health Inc 3.05%$ 3.051 millions
Bioventus Inc 3.05%$ 3.048 millions
Infusystem Holdings Inc3.02%$ 3.017 millions
Integra Lifesciences Holdings Corp2.27%$ 2.268 millions
Align Technology inc 1.97%$ 1.966 millions
Pediatrix Medical Group Inc 1.72%$ 1.724 millions


About Cytek Biosciences Inc Revenue Growth Rates (CTKB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Cytek Biosciences Inc (CIK 1831915).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-070259
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Cytek Biosciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.